bims-p53act Biomed News
on p53 mutations and anti-cancer therapy response
Issue of 2026–03–08
two papers selected by
Toni Martínez Bernabé, Universitat de les Illes Balears
  1. A rare diffuse follicular lymphoma with TP53 mutation and copy-neutral loss of heterozygosity at 1p36: insights into diagnosis, disease progression, and literature review.
  2. Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer.
  1. J Hematop. 2026 Mar 03. pii: 8. [Epub ahead of print]19(1):
    A rare diffuse follicular lymphoma with TP53 mutation and copy-neutral loss of heterozygosity at 1p36: insights into diagnosis, disease progression, and literature review.
    Mitra Abdolahi, Phassawan Rungsiprakarn, Ahmed Lazim, Pei Jianming, Nicholas Mackrides, Reza Nejati.
       BACKGROUND: Follicular lymphoma (FL) is a common type of non-Hodgkin lymphoma typically characterized by a nodular growth pattern and the t(14;18) translocation. A rare variant, FL with a predominantly diffuse growth pattern (dFL), lacks this translocation, demonstrates diffuse architecture, and is frequently associated with deletion of 1p36.
    CASE PRESENTATION: We report the case of a 43-year-old man who presented with an inguinal mass and was diagnosed with follicular lymphoma showing a predominantly diffuse pattern. Fluorescence in situ hybridization (FISH) analysis was negative for both BCL2 rearrangement and TNFRSF14 (1p36) deletion. Chromosomal microarray (CMA) and next-generation sequencing (NGS) were subsequently performed for further molecular characterization.
    RESULTS: CMA revealed copy-neutral loss of heterozygosity (cnLOH) at 1p36 and additional abnormalities involving 16p that were not detectable by FISH. NGS identified a TP53 mutation, a finding not previously reported in dFL and typically associated with more aggressive lymphoma behavior. Although dFL is generally considered an indolent and localized disease, the patient developed axillary recurrence within 1 year, requiring radiation therapy.
    CONCLUSION:  These findings underscore the importance of comprehensive molecular testing, such as NGS and CMA, to refine prognostic assessment and guide personalized treatment strategies for this rare lymphoma variant.
    Keywords:   TP53 mutation; 1p36; Copy-neutral loss of heterozygosity; Diffuse follicular lymphoma
    DOI:  https://doi.org/10.1007/s12308-026-00683-9
  2. J Exp Clin Cancer Res. 2026 Mar 03.
    Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer.
    Jia Chen, Qintao Ge, Jun He, Zichen Bian, Haoming Yu, Chun Li, Jialin Meng, Shuiping Yin, Zongyao Hao, Chaozhao Liang, Meng Zhang.
      
    Keywords:  CD8 + T cell; CXCL10-CXCR3 axis; Mutant p53; Prostate cancer; Single-cell RNA sequencing
    DOI:  https://doi.org/10.1186/s13046-026-03672-z
This page is being maintained by Thomas Krichel. It was last updated on 2026‒03‒09 at 11:21.